Abstract

The Section is the statistical and data management component of the Division of Clinical Sciences (DCS). The Section provides statistical leadership and data management consultation for major activities of the Division, and is involved in the design, conduct, monitoring, and statistical analyses of intramural and national multicenter clinical trials of experimental treatments for cancer, and intramural clinical trials for treatment of AIDS. Other major collaborative efforts include studies to identify important prognostic and treatment selection factors, evaluate diagnostic procedures, develop improved staging systems, and assist investigators in the design, execution, and analyses of major in vitro drug testing studies. The Section develops and implements new statistical designs and biometric methods related to the development and evaluation of new cancer and AIDS treatments. The Section maintains computerized data collection systems for intramural and national multicenter clinical protocols, and it works closely with interested branches to improve data recording and retrieval. The Section maintains a unified system for tracking basic information on all patients registered on DCS treatment protocols. Approximately 15% of the Sectionas activities are HIV-AIDS related.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC007202-17
Application #
6433371
Study Section
(BDMS)
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2000
Total Cost
Indirect Cost

  Institution

Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Schrump, David S; Fischette, Maria R; Nguyen, Dao M et al. (2008) Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 14:188-98
Gulley, James L; Aragon-Ching, Jeanny B; Steinberg, Seth M et al. (2008) Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 180:1432-7;discussion 1437
Eng-Wong, Jennifer; Orzano-Birgani, Jennifer; Chow, Catherine K et al. (2008) Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev 17:1696-701
Ahmad, Ejaz; Steinberg, Seth M; Goldin, Lynn et al. (2008) Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia. Cytometry B Clin Cytom 74:221-6
Portera, Chia C; Walshe, Janice M; Rosing, Douglas R et al. (2008) Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 14:2710-6
Klapper, Jacob A; Downey, Stephanie G; Smith, Franz O et al. (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113:293-301
Nakata, Hirotomo; Steinberg, Seth M; Koh, Yasuhiro et al. (2008) Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob Agents Chemother 52:2111-9
Azad, Nilofer S; Annunziata, Christina M; Steinberg, Seth M et al. (2008) Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer 112:1726-32
Dahut, William L; Scripture, Charity; Posadas, Edwin et al. (2008) A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14:209-14
Tan, A R; Steinberg, S M; Parr, A L et al. (2008) Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Ann Oncol 19:185-90

Showing the most recent 10 out of 127 publications